anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present in vitro and in vivo study aimed to fabricate and characterize linalool-zinc oxide nanoparticles (Lin-ZNP) and evaluate their effectiveness against Toxoplasma gondii infection in terms of inflammation, oxidative stress, and pathogenicity. Lin-ZNP was synthesized using an ethanolic solution of polyvinyl alcohol. The anti-Toxoplasma and cytotoxicity activities of Lin-ZNP were investigated, along with its effects on nitric oxide (NO) production, caspase-3 activity, and pro-inflammatory genes. After treating T. gondii-infected mice with Lin-ZNP for 14 days, the number and size of tissue cysts, antioxidant potential, pro-inflammatory cytokines, and T. gondii pathogenicity-related genes were evaluated by real-time polymerase chain reaction and Western blot analysis. The Lin-ZNP composite showed a reduced tendency with an average size of 105 nm. Lin-ZNP significantly reduced the viability of tachyzoites. The obtained selectivity index higher than 10, indicating high specificity for parasites with low cytotoxicity to normal cells. The Lin-ZNP significantly (p < 0.05) increased the production of NO, caspase-3 activity, and the expression levels of pro-inflammatory genes. Lin-ZNP significantly (p < 0.001) decreased the size and number of tissue cysts and caused a significant reduction in the level of malondialdehyde and a considerable increase (p < 0.001) in antioxidant enzymes and their expression genes. Lin-ZNP significantly downregulated both mRNA and protein expression of the inflammation-related markers associated with the TLRs/NF-κB pathway. The expression levels of the T. gondii pathogenicity-related genes were significantly downregulated (p < 0.05). The recent survey indicated that Lin-ZNP manages T. gondii infection by its antioxidant activity and inhibiting the TLRs/NF-κB pathway without toxicity in mice.
The study will compare the efficacy of PBT-A and health education program delivered via telehealth to parents on child weight management. Investigators will provide 6 months of a group program (PBT-A or HE) and will follow participants for 12-months post-treatment (total time = 18 months). Investigators will recruit parents of children diagnosed with autism and overweight or obesity. Assessments will occur at 5 timepoints: baseline, mid-treatment, post-treatment, 6-month and 12-month follow-up. Assessments will include anthropometry for both parent and child. Parent will also provide information regarding autism diagnosis and characteristics, eating behaviors, and parenting relationship measures. This program of research has the potential to advance the standard of practice for children with autism and overweight or obesity by developing tailored interventions which can be easily disseminated.
Disclosed is a shaving package. The shaving package includes a spray dispenser and a shaving formulation encapsulated in the spray dispenser. The shaving formulation includes an active ingredient and a plurality of inactive ingredients. The active ingredient includes an antiseptic agent. The plurality of inactive ingredients is selected from the group consisting of water, a surfactant, a salt, an acidifying agent, an antimicrobial preservative, a humectant, a chelating agent, a polycationic polymer, a peptide complex, a protein hydrolyzate composition, and a moisturizing agent. Further the spray dispenser includes a container for encapsulating the shaving formulation, a dispensing nozzle assembly coupled to the container and a pumping mechanism configured in the container and operatively coupled to the dispensing nozzle assembly. The dispensing nozzle assembly includes a discharge nozzle. The pumping mechanism is capable of pumping the shaving formulation out of the container through the discharge nozzle.
The invention discloses a processing method for drying a medicinal material radix astragali by microwave and infrared combination, aiming at the technical problems in the prior art that not only is the quality of medicinal materials affected but also various harmful substances can be brought in when traditional Chinese medicines are fumigated with sulfur. The method comprises the following steps: impurity removal, grading according to the size, smoothing straight, microwave drying, chilling, infrared drying, chilling, tidying, binding and tying and subpackaging. The method can achieve the aim of drying the medicinal material radix astragali faster. Compared with traditional methods, the method has the beneficial effect that the moisture content of the medicinal material can fast reach the limit stipulated in Chinese Pharmacopoeia on the basis of not reducing the main ingredients of the medicinal material. Compared with a sulfur fumigation method, the method has the beneficial effect that the harmful substances are prevented from being brought in. Meanwhile, the method has the beneficial effects that the medicinal material radix astragali has obvious effects on improvement of immunities of mice; mildewing, damages caused by worms and other phenomena are not easy to happen in the storage process; the stability of the quality of the medicinal material radix astragali is ensured; radix astragali processing is more normalized through tidying and subpackaging, thus improving the quality controllability of the medicinal material radix astragali.
Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
The invention discloses an umbilical therapy formula for treating blood stasis amenorrhea and a preparation method thereof, wherein the umbilical therapy formula comprises the following raw materials in parts by weight: 40 parts of peach kernel and 60 parts of copperas. Removing impurities from semen Persicae, soaking, and picking out semen Persicae and damaged skin and tip; grinding Melanteritum into superfine powder, and grinding into powder together with semen Persicae; pouring the powder into an iron pan, and parching with slow fire. Compared with the prior art, the invention has the following beneficial effects: the umbilical administration is convenient to operate, and normal work and life are not affected during treatment. (2) Navel skin is the thinnest, epidermis cutin is the thinnest, and medicine is easy to penetrate. Meanwhile, the umbilical peritoneal blood vessel is rich, and the external medicine is easy to absorb and rapidly enters the blood circulation, thereby achieving the physiotherapy purpose. (3) The umbilical administration can reduce the irritation of the medicine to gastrointestinal tract and reduce the influence of the medicine to liver and kidney functions.
<P>PROBLEM TO BE SOLVED: To shorten a period until medical image data is displayed.  <P>SOLUTION: Setting information in which a sequence with medical meaning is set as the sequence of viewing a plurality of medical image data is read from a portable medium in which a plurality of medical image data and the setting information are stored. Moreover, in accordance with the sequence set in the read setting information, a plurality of medical image data stored in the portable medium is replicated into a storage unit of a terminal device used for browsing of the image data. Furthermore, before replication is finished, reception of an output instruction to instruct output of prescribed medical image data to the output unit is started. Then, upon receiving the output instruction of the prescribed medical image data, the storage unit is searched for the medical image data predetermined in the output instruction, and the searched medical image data is output to an output unit.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Compositions, method and systems for bleaching tooth surfaces in an accelerated manner. The dental bleaching compositions include a bleaching agent and a stable radiant energy absorbing material that acts as a bleaching agent activator. The dental bleaching compositions of the present invention can be stable one-part compositions that do not require mixing at the time of treating a person's teeth but which remain stable over time. The dental bleaching composition is applied to the labial surface of teeth that are to be bleached. A source of radiant energy is directed onto the treated tooth surfaces to accelerate bleaching activity. The radiant energy source includes a dental light guide having an arcuate light directing member that is positioned in close proximity to the treated teeth. The light directing member has one or more light-emitting panels communicating with a radiant energy generating source that efficiently direct radiant energy onto the treated tooth surfaces. The dental light guide can irradiate all treated teeth of one or both dental arches simultaneously while in a fixed position relative to the one or both dental arches. The inventive dental compositions may also be activated using, e.g., conventional curing lights and lasers.
Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
The invention relates to a therapeutic polypeptide material serving to induce human resistance to bacterial and viral infection and stress without exerting substantial pyrogenic or antigenic action, being substantially free from polypeptides of molecular weight less than 1000, being heat-stable at least up to 100 DEG C., being soluble in liquid phenol, in water and in aqueous bases, being precipitatable from aqueous solution by phosphotungstic acid, being soluble in aqueous sulphosalicylic acid, showing a green fluorescence and containing the following amino acids in polypeptide form, namely glutamic acid, aspartic acid, arginine, lysine, alamine, serine, valine, leucine, isoleucine, glycine, phenylalanine, histidine, proline, tyrosine and threonine, being substantially free from combined phosphorus, exhibiting the reactions typical of hexosamines and a positive anthrone and biuret reaction and having an antimitotic effect against Hela and Chang cells.  The product is obtained by heating (e.g. to 100 DEG C.) an aqueous suspension or extract of an animal organ e.g. liver, kidney or spleen, and subjecting the product in aqueous solution to molecular fractionation to separate the required polypeptide from low molecular weight material.  Various methods of fractionating are disclosed.  In one example, fresh ox liver is treated with water containing phenol, heated to 100 DEG C. allowed to stand overnight, heated to 70 DEG C. and filtered, the filtrate concentrated, ethanol added, the precipitate removed and the ethanol extract concentrated to a paste.  An aqueous solution of the paste is stirred with asbestos and the separated asbestos is eluted with (a) liquid phenol and (b) ammonia.  These fractions are further treated on a Sephadex G50 column (cellulosic ion exchange resin). Pharmaceutical compositions comprise the above therapeutic polypeptide substance and a carrier e.g. capsules, tablets, dragees, suppositories, ampoules, syrups, linctuses, elixirs and emulsions.
The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
Nalmefene hydrochloride injection has been administered to reverse the effects of opioids after general anesthesia and in the treatment of overdose. It has also been used to reverse the systemic effects of intrathecal opioids.

Reversal of Postoperative Opioid Depression

Nalmefene hydrochloride injection (N=326) was studied in 5 controlled trials in patients who had received morphine or fentanyl intraoperatively. The primary efficacy criterion was the reversal of respiratory depression. A positive reversal was defined as both an increase in respiratory rate by 5 breaths per minute and a minimum respiratory rate of 12 breaths per minute. Five minutes after administration, initial single nalmefene hydrochloride injection doses of 0.1, 0.25, 0.5, or 1.0 µg/kg had effectively reversed respiratory depression in a dose-dependent manner. Twenty minutes after initial administration, respiratory depression had been effectively reversed in most patients receiving cumulative doses within the recommended range (0.1 to 1.0 µg/kg). Total doses of nalmefene hydrochloride injection above 1.0 µg/kg did not increase the therapeutic response. The postoperative administration of nalmefene hydrochloride at the recommended doses did not prevent the analgesic response to subsequently administered opioids.

Reversal of the Effect of Intrathecally Administered Opioids

Intravenous nalmefene hydrochloride at doses of 0.5 and 1.0 µg/kg was administered to 47 patients given intrathecal morphine. One to 2 doses of 0.5 and 1.0 µg/kg nalmefene hydrochloride reversed respiratory depression in most patients. The administration of nalmefene hydrochloride at the recommended doses did not prevent the analgesic response to subsequently administered opioids.

Management of Known or Suspected Opioid Overdose

Nalmefene hydrochloride injection (N=284) at doses of 0.5 mg to 2.0 mg was studied in 4 trials of patients who were presumed to have taken an opioid overdose. Nalmefene hydrochloride injection doses of 0.5 mg to 1.0 mg effectively reversed respiratory depression within 2 to 5 minutes in most patients subsequently confirmed to have opioid overdose. A total dose greater than 1.5 mg did not increase the therapeutic response.
Study protocol Nursing students who meet the inclusion criteria will be pre-tested and post-tested. The first test will be administered at baseline and the last test will be administered at week 8. The eight-week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh-week session will last approximately 150 minutes. The control group is expected to continue with their daily lives. There will be no intervention by the researcher during the research process. After the research is completed, the research team will hold an information meeting with the control group about the structured digital-based training content, and the materials used in the research will be given to the control group. The study will use simple randomization. https://www.random.org/ will be used to allocate students who meet the inclusion criteria to a specified number of groups. The data/outcome measures of the study (evaluator) will be blinded in terms of statisticians and reporting. Data collection tools: Personal Information Form, Disaster Literacy Scale, General Disaster Preparedness Belief Levels Scale based on the Health Belief Model.
The following adverse reactions have been identified during post-approval use of fosaprepitant. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possibleto reliably estimatetheir frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermalnecrolysis. [see Warnings and Precautions (5.2)].

Immune system disorders: hypersensitivity reactions including anaphylaxis and anaphylactic shock [see Contraindications (4), Warnings and Precautions (5.2)].

Nervous system disorders: ifosfamide-induced neurotoxicity reported after fosaprepitant and ifosfamide coadministration.
Attention functions have a major impact on children's social, school and emotional adjustment. They are one of the most common issues for prematurely born children with implications in academic and social-behavioral functioning. Prematurely born infants are often seen as having excessive mobility or being restless when it could be an adaptative answer to attention disorders leading to learning difficulties. Respecting spontaneous mobility could improve attention performance in vulnerable children. The aim of the study is to evaluate global attention performance of former premature children at the preschool age of 6 to 7 years. This evaluation will be done in three usual postures or mobility, and for the 3 attentional functions of orienting, alerting or executive control. They will be compared within the prematurely born children group and to term born controls of the same age. The Attention Network Test adapted to children by Rueda et al (Neuropsychologia 2004) using reaction time and accuracy to visual stimuli will be used to evaluate attention functions. Presentation of stimuli through virtual video glasses and collection of answers will be done thanks to a specific software.
Epidemiological evidence reveals that arsenic increases the risk of chronic kidney disease (CKD) in humans, but its mechanism of action has so far been unclear. Fibrosis is the manifestation of end-stage renal disease. Hypoxia is recognized as a vital event accompanying the progression of renal fibrosis. KM mice were exposed to 0, 20, 40, and 80 mg/L NaAsO2 for 12 weeks. HK-2 cells were treated with 1 μM NaAsO2 for 4 weeks. The results showed that arsenic increased the expression of hypoxia-inducible factor 1α (HIF-1α) (P < 0.05), which is involved in inorganic arsenic-induced renal fibrosis. The Hippo signaling pathway is the upstream signal of HIF-1α and the kinase cascade of Large tumor suppressor kinase 1 (LATS1) and Yes-associated protein 1 (YAP1) is the heart of the Hippo pathway. Our results showed that protein expressions of LATS1 and phosphorylated YAP1 were decreased, and dephosphorylated YAP1 expression increased in arsenic-treated mouse kidneys and human HK-2 cells (P < 0.05). Our research manifested that arsenic treatment suppressed the Hippo signaling and induced high expression of YAP1 into the nucleus. We also found that YAP1 was involved in arsenic-induced renal fibrosis by forming a complex with HIF-1α and maintaining HIF-1α stability. Our findings indicate that YAP1 is a potential target for molecular-based therapy for arsenic-mediated renal fibrosis.
The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
OBJECTIVES: The aim of this study was to evaluate the outcomes of transposition of the omentum into the mediastinum to support the replacement of infected aortic grafts or to cover infected aortic grafts that are not amenable for surgical replacement.
METHODS: All patients with thoracic aortic graft infections who underwent mediastinal transposition of the omentum at our institution between 2005 and 2023 were included in this study. Mediastinal transposition of the omentum was performed either after replacement of the infected graft ('curative concept') or solely as bailout procedure by wrapping the infected graft ('palliative concept'). The diagnosis, including computed tomography scans during follow-up, was made according to the criteria of the Management of Aortic Graft Infection Collaboration.
RESULTS: The patient cohort consisted of 31 patients. Both in-hospital and 1-year mortality were 0% (n = 0) for the curative concept (n = 9) compared to 23% (n = 5) and 41% (n = 9) for the palliative concept (n = 22), respectively. There was no graft infection-associated death or recurrence of infection after 3 years in the curative group. Survival was 52% at 3 years in the palliative group, with freedom of infection in 59% of the patients (n = 13).
CONCLUSIONS: Transposition of the omentum and wrapping of the infected aortic prosthetic graft is a useful bailout strategy for patients who are ineligible for replacement of an infected aortic graft. However, mortality stays high. For radical treatment of aortic graft infections, it may prove an effective supportive therapy and represents an important tool in the armamentarium of cardiac surgeons.
Medicine intervention is the major clinical treatment used to relieve the symptoms and delay the progression of rheumatoid arthritis (RA), but is limited by its poor targeted delivery and short therapeutic duration. Herein, we developed an injectable and bioadhesive gelatin-based (Gel) hydrogel as a local depot of leonurine (Leon)-loaded and folate-functionalized polydopamine (FA-PDA@Leon) nanoparticles for anti-inflammation and chondroprotection in RA. The nanoparticles could protect Leon and facilitate its entry into the M1 phenotype macrophage for intracellular delivery of Leon, while the hydrogel tightly adhered to the tissues in the joint cavity and prolonged the retention of FA-PDA@Leon nanoparticles, thus achieving higher availability and therapeutic efficiency of Leon. In vitro and in vivo experiments demonstrated that the Gel/FA-PDA@Leon hydrogel could strongly suppress the inflammatory response by down-regulating the JAK2/STAT3 signaling pathway in macrophages and protect the chondrocytes from ferritinophagy/ferroptosis. This contributed to maintaining the structural integrity of articular cartilage and accelerating the joint functional recovery. This work provides an effective and convenient strategy to achieve higher bioavailability and long-lasting therapeutic duration of medicine intervention in arthritis diseases.
BACKGROUND: We examined the role of psychological well-being related measures in explaining the associations between obesity and increased risk of non-communicable diseases (NCDs: hypertension, heart disease, stroke, diabetes, arthritis, cancer, and memory-related disease) in older adults.
METHODS: Data were from the English Longitudinal Study of Ageing (ELSA), UK (baseline: Wave 4-2008/2009; n = 8127) and the Health and Retirement Study (HRS), US (baseline: Waves 9 and 10-2008/2010; n = 12,477). Objective body mass index was used to define obesity. A range of psychological well-being related measures (e.g., depressive symptoms, life satisfaction) was available in ELSA (n = 7) and HRS (n = 15), and an index of overall psychological well-being was developed separately in each study. NCDs were from a self-reported doctor diagnosis and/or other assessments (e.g., biomarker data) in both studies; and in ELSA, NCDs from linked hospital admissions data were examined. Longitudinal associations between obesity status, psychological well-being measures, and NCDs were examined using Cox proportional hazard models (individual NCDs) and Poisson regression (a cumulative number of NCDs). Mediation by psychological well-being related measures was assessed using causal mediation analysis.
RESULTS: Obesity was consistently associated with an increased prospective risk of hypertension, heart disease, diabetes, arthritis, and a cumulative number of NCDs in both ELSA and HRS. Worse overall psychological well-being (index measure) and some individual psychological well-being related measures were associated with an increased prospective risk of heart disease, stroke, arthritis, memory-related disease, and a cumulative number of NCDs across studies. Findings from mediation analyses showed that neither the index of overall psychological well-being nor any individual psychological well-being related measures explained (mediated) why obesity increased the risk of developing NCDs in both studies.
CONCLUSION: Obesity and psychological well-being may independently and additively increase the risk of developing NCDs.